ReviewCancers2019
Pheochromocytomas and Paragangliomas: New Developments with Regard to Classification, Genetics, and Cell of Origin.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Algorithm of genetic diagnosis for patients with head and neck paraganglioma-update.Frontiers in neurology · 2024Pooled it
- Review
- A robust dual-readout ratiometric assay for dopamine based on NiMnRSC advances · 2026Article
- BUB1 as a candidate non-oncogene addiction vulnerability in metastatic phaeochromocytoma/paraganglioma.Scientific reports · 2026Article
- Presentation of a missense MDH2 variant in a Greek patient with pheochromocytoma.Hormones (Athens, Greece) · 2026Review
- [Personalized treatment of pheochromocytoma].Chirurgie (Heidelberg, Germany) · 2024Review
- Case report: A rare DLST mutation in patient with metastatic pheochromocytoma: clinical implications and management challenges.Frontiers in oncology · 2024Article
- Paraganglioma of the Neck: A Rare Case With Spinal Metastasis.Case reports in oncological medicine · 2024Article
- Genotype and clinical phenotype characteristics ofFrontiers in endocrinology · 2024Article
- Abdominal nonfunctional paraganglioma in which succinate dehydrogenase subunit B (SDHB) immunostaining was performed: a case report.Journal of medical case reports · 2023Article
- Lesion-based indicators predict long-term outcomes of pheochromocytoma and paraganglioma- SIZEPASS.Frontiers in endocrinology · 2023Article
- A young patient with heart failure was diagnosed with extra-adrenal paraganglioma: a case report.BMC cardiovascular disorders · 2022Article
- [Pheochromocytoma and paraganglioma during childhood and adolescence].Radiologie (Heidelberg, Germany) · 2022Review
- Progressive metastatic pheochromocytoma induced by multiple endocrine neoplasia type 2A with a lethal outcome.IJU case reports · 2022Article
- Computerized tomography texture analysis of pheochromocytoma: relationship with hormonal and histopathological data.Journal of endocrinological investigation · 2022Article
- Extensive patient-to-patient single nucleus transcriptome heterogeneity in pheochromocytomas and paragangliomas.Frontiers in oncology · 2022Article
- Case Report: Giant Paraganglioma of the Skull Base With Two Somatic Mutations inFrontiers in endocrinology · 2022Article
- Protocol for presurgical and anesthetic management of pheochromocytomas and sympathetic paragangliomas: a multidisciplinary approach.Journal of endocrinological investigation · 2021Review
- Insights into Mechanisms of Pheochromocytomas and Paragangliomas Driven by Known or New Genetic Drivers.Cancers · 2021Review
- Prevalence of Germline Variants in a Large Cohort of Japanese Patients with Pheochromocytoma and/or Paraganglioma.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors that arise in the adrenal medulla and in extra-adrenal locations, such as the head, neck, thorax, abdomen, and pelvis. Classification of these tumors into those with or without metastatic potential on the basis of gross or microscopic features is challenging. Recent insights and scoring systems have attempted to develop solutions for this, as described in the latest World Health Organization (WHO) edition on endocrine tumor pathology. PCC and PGL are amongst the tumors most frequently accompanied by germline mutations. More than 20 genes are responsible for a hereditary background in up to 40% of these tumors; somatic mutations in the same and several additional genes form the basis for another 30%. However, this does not allow for a complete understanding of the pathogenesis or targeted treatment of PCC and PGL, for which surgery is the primary treatment and for which metastasis is associated with poor outcome. This review describes recent insights into the cell of origin of these tumors, the latest developments with regard to the genetic background, and the current status of tumor classification including proposed scoring systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.